FDA's Nonprescription Drugs Advisory Committee set to consider vaginal douche safety.
This article was originally published in The Rose Sheet
Executive Summary
VAGINAL DOUCHE SAFETY CONSIDERATION BY NDAC is tentatively planned for mid-April. The Nonprescription Drugs Advisory Committee is interested in reviewing data from several studies suggesting that vaginal douche products may lead to a higher incidence of acute pelvic inflammatory disease. The products have also been linked to elevated risk of ectopic pregnancy and may cause irritation, sensitization, and changes in vaginal flora and pH.